Tune Therapeutics News and Resources

Tune Therapeutics, a leading epigenome editing company, has secured over $175 million in financing to further the development of its innovative therapies targeting chronic and common diseases. The funding round was led by prominent investors including New Enterprise Associates, Yosemite,